Impact of imatinib on the pharmacokinetics and in vivo efficacy of etoposide and/or ifosfamide

BMC Pharmacology

Volumn 7, Issue , 2007, Pages

  Rezaï, Keyvan ^a   Lokiec, François ^a   Grandjean, Isabelle ^b   Weill, Sophie ^a   de Cremoux, Patricia ^b   Bordier, Vincent ^b   Ekue, Richard ^b   Garcia, Mickael ^b   Poupon, Marie France ^b   Decaudin, Didier ^b  

^a CENTRE RENÉ HUGUENIN   (France)

^b INSTITUT CURIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ETOPOSIDE; FLUCONAZOLE; GEMCITABINE; IFOSFAMIDE; IMATINIB; SODIUM CHLORIDE; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG FATALITY; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG POTENTIATION; DRUG URINE LEVEL; FEMALE; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; KIDNEY CLEARANCE; LIVER CLEARANCE; LUNG SMALL CELL CANCER; MONOTHERAPY; MOUSE; NONHUMAN; NUDE MOUSE; ONCOGENE C KIT; PLASMA CONCENTRATION-TIME CURVE; ANIMAL; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLISM; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG SYNERGISM; ETOPOSIDE; FEMALE; HUMANS; IFOSFAMIDE; LUNG NEOPLASMS; MICE; MICE, NUDE; PIPERAZINES; PYRIMIDINES; TRANSPLANTATION, HETEROLOGOUS;

EID: 38049146032     PISSN: None     EISSN: 14712210     Source Type: Journal    
DOI: 10.1186/1471-2210-7-13     Document Type: Article

References (50)

1. Druker BJ Tamura S Buchdunger E Ohno S Segal GM Fanning S Zimmermann J Lydon NB Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of BCR-Abl positive cells Nat Med 1996, 2:561-566. 10.1038/ nm0596-561 8616716
2. Carroll M Ohno-Jones S Tamura S Buchdunger E Zimmermann J Lydon NB Gilliland DG Druker BJ CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins Blood 1997, 90(12):4947-4952. 9389713
3. Dewar AL Cambareri AC Zannettino AC Miller BL Doherty KV Hughes TP Lyons AB Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib Blood 2005, 105:3127-3132. 10.1182/blood-2004-10-3967 15637141
4. Decaudin D de Cremoux P Sastre X Judde JG Némati F Tran-Perennou C Fréneaux P Livartowski A Pouillart P Poupon M-F In vivo efficacy of STI571 in xenografted human small cell lung cancer alone or combined with chemothe Int J Cancer 2005, 113:849-856. 10.1002/ijc.20652 15499612
5. Pietras K Ostman A Sjoquist M Buchdunger E Reed RK Heldin CH Rubin K Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors Cancer Res 2001, 61:2929-2934. 11306470
6. Miyamoto T Sasaguri Y Sugama K Azakami S Morimatsu M Expression of the c-kit mRNA in human aortic endothelial cells Biochem Mol Biol Int 1994, 34:513-520. 7530545
7. Langley RR Fan D Tsan RZ Rebhun R He J Kim SJ Fidler IJ Activation of the platelet-derived growth factor-receptor enhances survival of murine bone endothelial cells Cancer Res 2004, 64:3727-3730. 10.1158/ 0008-5472.CAN-03-3863 15172974
8. Matsui J Wakabayashi T Asada M Yoshimatsu K Okada M Stem cell factor/ c-kit signaling promotes the survival, migration, and capillary tube formation of human umbilical vein endothelial cells J Biol Chem 2004, 279:18600-18607. 10.1074/jbc.M311643200 14985355
9. Platzer P Herzog W Thalhammer T Hamilton G Haberl I Jager W Formation of a novel topotecan metabolite in the hormone-independent human prostate carcinoma cell lines DU-145 and PC-3 Anticancer Res 1998, 18:2737-2741. 9703938
10. Kerbusch T Jansen RL Mathot RA Huitema AD Jansen M van Rijswijk RE Beijnen JH Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin Clin Pharmacol Ther 2001, 70:132-141. 10.1067/mcp.2001.117283 11503007
11. Deininger MWN O'Brien SG Ford JM Druker BJ Practical management of patients with chronic myeloid leukemia receiving imatinib J Clin Oncol 2003, 21:1637-1647. 10.1200/JCO.2003.11.143 12668652
12. Toffoli G Corona G Basso B Boiocchi M Pharmacokinetic optimisation of treatment with oral etoposide Clin Pharmacokinet 2004, 43:441-466. 10.2165/00003088-200443070-00002 15139794
13. Decaudin D Baran Marszak F Némati F Mathiot C Martin A Némati F Lantz O di Santo J Arnaud P Bordier V Vincent-Salomon A Poupon MF High efficacy of combined rituximab and gemcitabine on EBV-associated human B-cell lymphoma obtained after Hodgkin's xenograft in immunodeficient mice Anti-Cancer drugs 2006, 17:685-695. 10.1097/ 01.cad.0000215061.78189.4e 16917214
14. Poupon M-F Arvelo F Goguel AF Bourgeois Y Jacrot M Hanania N Response of small-cell lung cancer xenografts to chemotherapy: Multidrug resistance and direct clinical correlates J Natl Cancer Inst 1993, 85:2023-2029. 10.1093/jnci/85.24.2023 7902445
15. Harvey VJ Joel SP Johnston A Slevin ML High performance liquid chromatography of etoposide in plasma and urine J Chromatogr 1985, 339:419-423. 10.1016/S0378-4347(00)84674-5 4008582
16. de Bruijn EA Slee PH Van Oosterom AT Lameijer DW Roozendaal KJ Tjaden UR Pharmacokinetics of intravenous and oral cyclophosphamide in the presence of methotrexate and fluorouracil Pharm Weekbl Sci 1988, 10:200-206. 3205676
17. de Cremoux P Tran-Perennou C Brockdorff B Boudou E Brunner N Magdelenat H Lykkesfeldt AE Validation of real-time RT-PCR for analysis of human breast cancer cell lines resistant or sensitive to treatment with antiestrogens Endocr Relat Cancer 2003, 10:409-484. 10.1677/ erc.0.0100409 14503918
18. Spyratos F Bouchet C Tozlu S Labroquere M Vignaud S Becette V Lidereau R Bieche I Prognostic value of uPA, PAI-1 and PAI-2 mRNA expression in primary breast cancer Anticancer Res 2002, 22:2997-3003. 12530032
19. Pinto A Gloghini A Gattei V Aldinucci D Zagonel C Carbone A Expression of the c-kit receptor in human lymphomas is restricted to Hodgkin's disease and CD30+ anaplastic large cell lymphomas Blood 1994, 83:785-792. 7507733
20. Ocqueteau M Orfao A Garcia-Sanz R Almeida J Gonzalez M San Miguel JF Expression of the CD117 antigen (c-Kit) on normal and myelomatous plasma cells Br J Haematol 1996, 95:489-493. 8943889
21. Potti A Ganti AK Kargas S Koch M Immunohistochemical detection of C-kit (CD117) and vascular endothelial growth factor (VEGF) overexpression in mantle cell lymphoma Anticancer Res 2002, 22:2899-2901. 12530014
22. Potti A Ganti AK Koch M Levitt R Mehdi SA Immunohistochemical identification of HER-2/neu overexpression and CD117 (c-kit) expression in multiple myeloma Leuk Lymphoma 2002, 43:2427-2430. 10.1080/ 1042819021000040198 12613538
23. Bayer-Garner IB Schwartz MR Lin P Smoller BR CD117, but not lysozyme, is positive in cutaneous plasmacytoma Arch Pathol Lab Med 2003, 127:1596-1598. 14632572
24. Brauns TC Schultewolter T Dissemond J Maschke J Goos M C-KIT expression in primary cutaneous T-cell lymphomas. C-KIT expression in primary cutaneous T-cell lymphomas J Cutan Pathol 2004, 31:577-582. 10.1111/ j.0303-6987.2004.00182.x 15330987
25. Kraj M Poglod R Kopec-Szlezak J Sokolowska U Wozniak J Kruk B C-kit receptor (CD117) expression on plasma cells in monoclonal gammopathies Leuk Lymphoma 2004, 45:2281-2289. 10.1080/10428190412331283279 15512818
26. Li J Luo SK Zhang GC Hong WD Tong XZ Expression of CD117 antigen on multiple myeloma and its significance Ai Zheng 2004, 23:951-954. 15301722
27. Lugli A Went P Khanlari B Nikolova Z Dirnhofer S Rare KIT (CD117) expression in multiple myeloma abrogates the usefulness of imatinib mesylate treatment Virchows Arch 2004, 444:264-268. 10.1007/ s00428-003-0934-8 14677065
28. Rassidakis GZ Georgakis GV Oyarzo M Younes A Medeiros LJ Lack of c-kit (CD117) expression in CD30+ lymphomas and lymphomatoid papulosis Mod Pathol 2004, 17:946-953. 10.1038/modpathol.3800144 15105813
29. Zimpfer A Went P Tzankov A Pehrs AC Lugli A Maurer R Terracciano L Pileri S Dirnhofer S Rare expression of KIT (CD117) in lymphomas: A tissue microarray study of 1166 cases Histopathology 2004, 45:398-404. 10.1111/j.1365-2559.2004.01968.x 15469479
30. Vaniaki E Cattoretti G Colovai AI Murty VV Alobeid B Bhagat G CD117 expression in diffuse large B-cell lymphomas: Fact or fiction? Pathol Int 2005, 55:716-723. 10.1111/j.1440-1827.2005.01893.x 16271084
31. Li T Zhang B Ye Y Yin H Immunohistochemical and genetic analysis of Chinese nasal natural killer/T-cell lymphomas Hum Pathol 2006, 37:54-60. 10.1016/j.humpath.2005.09.020 16360416
32. Ergin M Denning MF Izban KF Amin HM Martinez RL Saeed S Alkan S Inhibition of tyrosine kinase activity induces caspase-dependent apoptosis in anaplastic large cell lymphoma with NPM-ALK (p80) fusion protein Exp Hematol 2001, 29:1082-1090. 10.1016/S0301-472X(01)00688-9 11532349
33. Re D Wickenhauser C Ahmadi T Buchdunger E Kochanek M Diehl V Wolf J Preclinical evaluation of the antiproliferative potential of STI571 in Hodgkin's disease Br J Cancer 2002, 86:1333-1335. 10.1038/sj.bjc.6600243 11953894
34. Pandiella A Carvajal-Vergara X Tabera S Mateo G Gutierrez N San Miguel JF Imatinib mesylate (STI571) inhibits multiple myeloma cell proliferation and potentiates the effect of common antimyeloma agents Br J Haematol 2003, 123:858-888. 10.1046/j.1365-2141.2003.04706.x 14632777
35. Dispenzieri A Gertz MA Lacy MQ Geyer SM Greipp PR Rajkumar SV Kimlinger T Lust JA Fonseca R Allred J Witzig TE A phase II trial of imatinib in patients with refractory/relapsed myeloma Leuk Lymphoma 2006, 47:39-42. 10.1080/10428190500271269 16321825
36. Kuroda J Kimura S Segawa H Kobayashi Y Yoshikawa T Urasaki Y Ueda T Enjo F Tokuda H Ottmann OG Maekawa T The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate Blood 2003, 102:2229-2235. 10.1182/blood-2003-01-0305 12763930
37. Orsolic N Giles FJ Gourdeau H Golemovic M Beran M Cortes J Freireich EJ Kantarjian H Verstovsek S Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: Preclinical evaluation Br J Haematol 2004, 124:727-738. 10.1111/j.1365-2141.2004.04831.x 15009060
38. O'Reilly T Wartmann M Maira SM Hattenberger M Vaxelaire J Muller M Ferretti S Buchdunger E Altmann KH McSheehy PM Patupilone (epothilone B, EPO906) and imatinib (STI571, Glivec) in combination display enhanced antitumour activity in vivo against experimental rat C6 glioma Cancer Chemother Pharmacol 2005, 55:307-317. 10.1007/s00280-004-0913-z 15723258
39. Corcoran NM Costello AJ Combined low-dose imatinib mesylate and paclitaxel lack synergy in an experimental model of extra-osseous hormone-refractory prostate cancer BJU Int 2005, 96(4):640-646. 10.1111/ j.1464-410X.2005.05699.x 16104925
40. Gardembas M Rousselot P Tulliez M Vigier M Buzyn A Rigal-Huguet F Legros L Michallet M Berthou C Cheron N Maloisel F Mahon FX Facon T Berthaud P Guilhot J Guilhot F CML French Group Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase Blood 2003, 102:4298-4305. 10.1182/blood-2003-04-1010 12933584
41. Tsimberidou AM Colburn DE Welch MA Cortes JE Verstovsek S O'Brien SM Albitar M Kantarjian HM Giles FJ Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders Cancer Chemother Pharmacol 2003, 52:229-234. 10.1007/ s00280-003-0651-7 12783207
42. Mathew P Thall PF Jones D Perez C Bucana C Troncoso P Kim SJ Fidler IJ Logothetis C Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: A modular phase I trial in androgen-independent prostate cancer J Clin Oncol 2004, 22:3323-3329. 10.1200/JCO.2004.10.116 15310776
43. Thomas DA Faderl S Cortes J O'Brien S Giles FJ Kornblau SM Garcia-Manero G Keating MJ Andreeff M Jeha S Beran M Verstovsek S Pierce S Letvak L Salvado A Champlin R Talpaz M Kantarjian H Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate Blood 2004, 103:4396-4407. 10.1182/blood-2003-08-2958 14551133
44. Dresemann G Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: A patient series Ann Oncol 2005, 16:1702-1708. 10.1093/annonc/mdi317 16033874
45. Lee KH Lee JH Choi SJ Lee JH Seol M Lee YS Kim WK Lee JS Seo EJ Jang S Park CJ Chi HS Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia Leukemia 2005, 19:1509-1516. 10.1038/sj.leu.2403886 16034462
46. Reardon DA Egorin MJ Quinn JA Rich JN Gururangan S Vredenburgh JJ Desjardins A Sathornsumetee S Provenzale JM Herndon JE II Dowell JM Badruddoja MA McLendon RE Lagattuta TF Kicielinski KP Dresemann G Sampson JH Friedman AH Salvado AJ Friedman HS Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme J Clin Oncol 2005, 23:9359-9368. 10.1200/JCO.2005.03.2185 16361636
47. George S Desai J Paul Eder J Manola J Ryan DP Appleman LJ Demetri GD Selective kinase inhibition with daily imatinib intensifies toxicity of chemotherapy in patients with solid tumours Eur J Cancer 2006, 4:864-870. 10.1016/j.ejca.2005.12.010
48. Johnson FM Krug LM Tran HT Shoaf S Prieto VG Tamboli P Peeples B Patel J Glisson BS Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma Cancer 2006, 106:366-374. 10.1002/cncr.21640 16342249
49. Rea D Legros L Raffoux E Thomas X Turlure P Maury S Dupriez B Pigneux A Choufi B Reman O Stephane D Royer B Vigier M Ojeda-Uribe M Recher C Dombret H Huguet F Rousselot P Intergroupe Francais des Leucemies Myeloides Chronique; Group for Research in Adult Acute Lymphoblastic Leukemia High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia Leukemia 2006, 20:400-403. 10.1038/sj.leu.2404115 16437142
50. Yanada M Takeuchi J Sugiura I Akiyama H Usui N Yagasaki F Kobayashi T Ueda Y Takeuchi M Miyawaki S Maruta A Emi N Miyazaki Y Ohtake S Jinnai I Matsuo K Naoe T Ohno R Japan Adult Leukemia Study Group High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: A phase II study by the Japan Adult Leukemia Study Group J Clin Oncol 2006, 24:460-466. 10.1200/JCO.2005.03.2177 16344315